Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. (DFTX) director Carol A. Vallone reported exercising stock options on September 18, 2026 to acquire 1,086 Common Shares at an exercise price of $35.52 per share. Following the transaction, she directly holds 22,296 Common Shares, and the exercised option position is reduced to zero.
Definium Therapeutics, Inc. (DFTX) director Andreas Krebs exercised stock options covering 1,629 Common Shares on September 18, 2026, at an exercise price of $35.52 per share. The option position reported was fully exercised, and his direct holdings increased to 21,402 Common Shares. No Rule 10b5-1 trading plan is reported.
Definium Therapeutics, Inc. (DFTX) reported that its Chief Medical Officer, Daniel Karlin, acquired 200,000 common shares on September 14, 2026 through a grant categorized as a grant or award, at a reported price of $0.00 per share. These shares represent the third tranche of performance share units granted effective March 12, 2025, which remain subject to vesting based on Dr. Karlin’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones. Following this grant and including 417 shares acquired under the 2024 Employee Share Purchase Plan on August 17, 2026, Dr. Karlin directly holds 803,699 common shares. No Rule 10b5-1 trading plan is reported for this transaction.
Definium Therapeutics, Inc. (symbol: DFTX) is the issuer of record for a Form 4 filing submitted to the SEC. Wiley Matthew T. reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. (DFTX) reported that Chief Commercial Officer Matthew T. Wiley received a grant of 125,000 common shares on September 14, 2026, as the third tranche of performance share units originally granted effective March 17, 2025. These shares remain subject to vesting based on Wiley’s continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley directly holds 362,133 common shares. No Rule 10b5-1 trading plan is reported in connection with this grant.
Definium Therapeutics, Inc. (DFTX) reported that its Chief Legal Officer, Mark Sullivan, acquired 125,000 common shares on September 14, 2026 as a grant of performance share units. These shares represent the third tranche of units granted effective March 12, 2025 and remain subject to vesting based on his continued employment through March 12, 2028 and achievement of specified clinical and regulatory milestones. Following this grant, Sullivan holds 508,279 common shares directly, including 208 shares previously acquired under the company’s 2024 Employee Share Purchase Plan. No Rule 10b5-1 trading plan is reported for this award.
Definium Therapeutics, Inc. (DFTX) reported that its Chief Financial Officer, Brandi Roberts, received a grant of 125,000 common shares on September 14, 2026 as a performance share unit (PSU) award. These shares are part of the third tranche of PSUs granted effective June 2, 2025 and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Roberts directly holds 397,905 common shares, which include 918 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026. No Rule 10b5-1 trading plan is reported for this transaction.
Definium Therapeutics, Inc. (DFTX) reported that Chief Executive Officer and director Robert Barrow was credited with 750,000 common shares on September 14, 2026 as a grant/award acquisition at a reported price of $0.00 per share, bringing his directly held stake to 2,244,640 common shares.
According to the accompanying footnote, these common shares represent the third tranche of performance share units originally granted effective March 12, 2025 and they remain subject to vesting based on Mr. Barrow’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. No Rule 10b5-1 trading plan is reported for this award.
Definium Therapeutics, Inc. (DFTX) reported positive topline results from Panorama, its second Phase 3 trial of DT120 ODT in generalized anxiety disorder. DT120 ODT 100 µg achieved a placebo-adjusted 5.1-point improvement on the Hamilton Anxiety Rating Scale (HAM-A) at Week 12 (p<0.0001; effect size d=0.64), meeting the primary endpoint and all key secondary endpoints.
Efficacy was rapid, with statistically significant benefits on HAM-A as early as Week 1 and on CGI-S by Day 2, and was consistent with prior dose–response data. A 50 µg arm showed smaller effects, supporting 100 µg as the lead dose. Panorama is Definium’s third positive Phase 3 readout for DT120 ODT across GAD and MDD.
DT120 ODT 100 µg was generally well tolerated, with no drug-related serious adverse events and no suicidality signal, though treatment-emergent adverse events were common and largely expected psychedelic effects such as illusions and nausea. A pre-NDA meeting with the FDA is scheduled for 4Q 2026, with an NDA filing for DT120 ODT anticipated in 1H 2027. Definium reported approximately $1.1 billion in cash, cash equivalents and investments as of June 30, 2026, and estimates cash runway into 2030.
Definium Therapeutics, Inc. (DFTX) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its DT120 (lysergide) orally disintegrating tablet (ODT) for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation for the DT120 program, following an earlier designation in generalized anxiety disorder (GAD).
The designation is based on results from the Phase 3 Emerge study, where a single 100 µg dose of DT120 ODT achieved a statistically significant 8.1‑point placebo‑adjusted improvement in Montgomery‑Åsberg Depression Rating Scale (MADRS) total score at Week 6 (p<0.0001), with efficacy described as durable through Week 12. DT120 ODT is a proprietary, pharmaceutically optimized LSD formulation using Zydis ODT fast‑dissolve technology, intended to improve onset, bioavailability and tolerability.
Definium highlights the large unmet need in MDD, where more than 21 million U.S. adults experience a major depressive episode annually and fewer than one‑third achieve remission with first‑line treatments, and notes a multi‑layered intellectual property strategy to protect the DT120 ODT franchise.
Definium Therapeutics, Inc. (DFTX) reported that Chief Executive Officer and director Robert Barrow received an award of 40,000 common shares on September 2, 2026, representing the first tranche of performance share units originally granted effective February 3, 2026, which vest based on specified clinical and regulatory milestones. This amount also includes 417 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.
On September 3, 2026, Barrow sold 19,023 common shares to satisfy withholding tax obligations related to the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. The reported weighted average sales price was $37.94 per share, with individual trades executed between $37.46 and $38.94 per share.